All In Biotech

Drug Trial Radar · NCT05458219

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

A Phase 1a/b, Multicenter, Open-label, First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 470 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

470

Planned (sponsor's estimate)

Start

Oct 26, 2022

Primary completion

Jun 30, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
Collaborators
Fortvita Biologics (USA)Inc.; TigerMed
First posted
Jul 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ia/Ib, multicenter, open-label, first-in-human study to evaluate the safety, tolerability, PK, and efficacy of IBI343 in participants with locally advanced unresectable or metastatic solid tumors. It is planned to be carried out in different countries or regions such as China, Australia and US. There are three parts in phase Ia. Part 1 includes dose escalation and expansion phase and part 2 is designed for dose optimization for IBI343 monotherapy. Part 3 1L G/GEJ AC and 1L PDAC cohorts will include an initial safety lead-in stage to confirm the tolerability of IBI343 in combination with chemotherapy in 1L PDAC and G/GEJ AC, followed by a randomized dose-optimization stage designed to further characterize safety, pharmacokinetics, and preliminary efficacy to inform selection of the recommended Phase 3 dose.

Conditions

  • Locally Advanced Unresectable or Metastatic Solid Tumors

Interventions

  • IBI343Drug

    IBI343 will be administered intravenously (IV) on Day 1 of every 21-day cycle.

  • FOLFIRINOX/mFOLFIRINOXDrug

    FOLFIRINOX/mFOLFIRINOX will be administered IV Q2W on Days 1-3 every 2 weeks (14 days).

  • mFOLFOXDrug

    mFOLFOX will be administered IV Q2W on Days 1-3 every 2 weeks (14 days) in each cycle after IBI343

  • IBI343Drug

    IBI343 will be administered IV Q2W on Day1 (14 days).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events(AEs), treatment emergent adverse event (TEAEs),serious adverse events (SAEs)Time frame: Up to 90 days after the last administration
  2. Dose-limiting Toxicity (DLT)Time frame: 21 days after the first dose of IBI343
  3. To determine RP2D of IBI343.Time frame: Up to 2 years
  4. ORR assessed by the investigator based on RECIST version 1.1.Time frame: Up to 2 years
  5. Number of subjects with clinically significant changes in physical examination resultsTime frame: Up to 2 years
  6. Number of participants with abnormal vital signsTime frame: Through study completion, up to 2 years
  7. Objective response rate (ORR)Time frame: ORR is defined as the proportion of participants with a completeresponse (CR) or partial response (PR)
  8. Number of participants with abnormal laboratory tests resultsTime frame: Through study completion, up to 2 years
  9. Number of participants with abnormal vital signsTime frame: Through study completion, up to 2 years
  10. Number of participants with abnormal vital signsTime frame: Through study completion, up to 2 years
  11. Number of participants with abnormal vital signsTime frame: Through study completion, up to 2 years
  12. Number of participants with abnormal laboratory tests resultsTime frame: Through study completion, up to 2 years
  13. Number of participants with abnormal laboratory tests resultsTime frame: Through study completion, up to 2 years
  14. Number of participants with abnormal laboratory tests resultsTime frame: Through study completion, up to 2 years
  15. Number of participants with abnormal laboratory tests resultsTime frame: Through study completion, up to 2 years
  16. Number of participants with abnormal laboratory tests resultsTime frame: Through study completion, up to 2 years
  17. Number of participants with abnormal laboratory tests resultsTime frame: Through study completion, up to 2 years

Locations

39 sites in 3 countries. Site status is shown where the registry gives one.

  • Next Oncology-Austin

    Austin, Texas · Recruiting

  • Next Oncology-Dallas

    Irving, Texas · Recruiting

  • Next Oncology-San Antonio

    San Antonio, Texas · Recruiting

  • St Vincent's Hospital Sydney

    Darlinghurst, New South Wales, Australia · Recruiting

  • Cancer Care Wollongong

    Wollongong, New South Wales, Australia · Recruiting

  • Pindara Private Hospital

    Benowa, Queensland, Australia · Active not recruiting

  • Sunshine Coast University Private Hospital

    Birtinya, Queensland, Australia · Recruiting

  • Anhui Cancer Hospital

    Hefei, Anhui, China · Recruiting

  • Anhui Provincial Hospital

    Hefei, Anhui, China · Recruiting

  • The First Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Tumor Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Sun Yat-sen Memorial Hospital Sun Yat-Sen university

    Guangzhou, Guangzhou, China · Recruiting

  • The First Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangzhou, China · Recruiting

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Hubei Cancer Hospital

    Wuhan, Hubei, China · Recruiting

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technolog

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China · Recruiting

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • Ningxia Medical University General Hospital

    Yinchuan, Ningxia, China · Recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China · Recruiting

  • Jinan Central Hospital

    Jinan, Shandong, China · Recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Recruiting

  • Jining First People's Hospital

    Jining, Shandong, China · Recruiting

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • Renji Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • Tianjin Cancer Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China · Recruiting

  • Ningbo Medical Center Li Huili Hospital

    Ningbo, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.